Related Experiment Video
Updated: May 27, 2026
08:13
Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test (OGTT) and Insulin Tolerance Test (ITT)
Published on: January 7, 2018
Insulin resistance, hyperglycemia, and atherosclerosis
1Department of Pathology, Diabetes and Obesity Center of Excellence, 815 Mercer Street, University of Washington, Seattle, WA 98109, USA.
Cell Metabolism
|November 8, 2011
Summary
Type 2 diabetes hinders progress in preventing atherosclerotic coronary artery disease (CAD). Understanding how insulin resistance and hyperglycemia worsen atherosclerosis is key to developing new treatments for diabetic cardiovascular disease.
Area of Science:
- Cardiovascular Medicine
- Endocrinology
- Metabolic Diseases
Background:
- Coronary artery disease (CAD) prevention is challenged by the rise of type 2 diabetes.
- Type 2 diabetes is linked to increased cardiovascular risk, necessitating a deeper understanding of its mechanisms.
- Key features of type 2 diabetes, insulin resistance and hyperglycemia, are implicated in atherosclerosis progression.
Purpose of the Study:
- To elucidate the impact of insulin resistance and hyperglycemia on the development and progression of atherosclerosis in the context of type 2 diabetes.
- To investigate the role of defective insulin signaling within atherosclerotic lesions.
- To clarify the contribution of hyperglycemia to CAD in type 2 diabetes patients.
Main Methods:
- Review of current literature on type 2 diabetes, insulin resistance, hyperglycemia, and atherosclerosis.
- Analysis of cellular and molecular mechanisms linking metabolic dysfunction to vascular disease.
- Examination of epidemiological data on CAD prevalence in diabetic populations.
Main Results:
- Insulin resistance is associated with systemic CAD risk factors.
- Evidence suggests impaired insulin signaling in lesional cells contributes to atherosclerosis.
- The specific role of hyperglycemia in exacerbating CAD remains less defined.
Conclusions:
- Understanding the interplay between type 2 diabetes, insulin resistance, hyperglycemia, and atherosclerosis is crucial for advancing CAD prevention.
- Targeting mechanisms of insulin resistance and hyperglycemia may offer novel therapeutic strategies for atherosclerotic vascular disease in diabetic patients.
- Further research is needed to fully elucidate the role of hyperglycemia in diabetic CAD.
More Related Videos
Related Concept Videos
01:24Type II Diabetes II: Pathophysiology
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
01:29Hyperglycemia
Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:19Type I Diabetes III: Clinical Manifestations
Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...
01:26Type II Diabetes I: Introduction
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
01:22Complications of Diabetes Mellitus
Diabetes mellitus is a chronic metabolic disorder characterized by persistent hyperglycemia due to insulin deficiency, resistance, or both. Prolonged hyperglycemia disrupts metabolic homeostasis and leads to acute and chronic complications.Acute ComplicationsAcute complications result from sudden metabolic imbalance.Diabetic ketoacidosis (DKA) mainly appears in type 1 diabetes but may also develop in type 2 diabetes, particularly under extreme stress. It arises from severe insulin deficiency,...